🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "significant breakthrough" in the battle against drug-resistant strains of the pathogen, according to health experts.

A Worldwide Public Health Issue

The sexually transmitted infection are on the rise around the world, with data suggesting more than 82 million instances each year. Particularly high rates are seen in Africa and nations within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. Across England, cases have hit a record high, while rates across Europe in 2023 were three times higher compared to those in 2014.

“The clearance of fresh medications for gonorrhoea is an critical and opportune development in the reality of rising global incidence, escalating drug resistance and the extremely scarce therapeutic options presently on offer.”

Public health authorities are increasingly worried about the increase in antibiotic-resistant strains. The WHO has listed it as a "critical concern". Recent surveillance revealed that the effectiveness of primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Therapies Receive Authorization

One new antibiotic, alternatively called a brand name, was cleared by the US FDA in mid-December for treating gonorrhoea. This infection can lead to major issues, including infertility. Experts anticipate that focused deployment of this new drug will help slow the spread of drug resistance.

Gepotidacin, created by the drugmaker GSK, was also approved in close succession. This treatment, which is employed against urinary tract infections, was shown in trials to be able to combat superbug versions of the gonorrhoea bacteria.

An Innovative Approach to Creation

This new treatment emerged from a unique collaborative effort for medication research. The non-profit organisation GARDP collaborated with the pharmaceutical company Innoviva to develop it.

“This approval represents a huge turning point in the therapy of multidrug-resistant gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Clinical Trial Results and Worldwide Availability

Based on findings published in a major medical journal, zoliflodacin cured more than 90% of genital gonorrhoea infections. This puts it on an similar efficacy with the typical regimen, which uses a dual-drug approach. The study involved hundreds of volunteers from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, the non-profit has the rights to make available and distribute the drug in a wide range of low-income and middle-income countries.

Medical professionals on the front lines have shared optimism. The availability of a one-pill regimen like this is hailed as a "critical tool" for gonorrhoea control. This is considered essential to alleviate the strain of the infection for individuals and to stop the proliferation of untreatable gonorrhoea worldwide.